With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL? Available to Purchase

2.

Brown

PA

,

Ji

L

,

Xu

X

, et al.

Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial

.

JAMA

.

2021

;

325

(

9

):

833

-

842

.

3.

van der

Sluis IM

,

de Lorenzo

P

,

Kotecha

RS

, et al.

Blinatumomab added to chemotherapy in infant lymphoblastic leukemia

.

N Engl J Med

.

2023

;

388

(

17

):

1572

-

1581

.

4.

Locatelli

F

,

Zugmaier

G

,

Rizzari

C

, et al.

Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial

.

JAMA

.

2021

;

325

(

9

):

843

-

854

.

5.

Hogan

LE

,

Brown

PA

,

Ji

L

, et al.

Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse

.

J Clin Oncol

.

2023

;

41

(

25

):

4118

-

4129

.

6.

Bassan

R

,

Chiaretti

S

,

Della Starza

I

, et al.

Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study

.

Blood

.

2025

;

145

(

21

):

2447

-

2459

.

7.

Litzow

MR

,

Sun

Z

,

Mattison

RJ

, et al.

Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults

.

N Engl J Med

.

2024

;

391

(

4

):

320

-

333

.

8.

Jabbour

E

,

Short

NJ

,

Jain

N

, et al.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

1

):

e24

-

e34

.

9.

Short

NJ

,

Kantarjian

H

,

Jain

N

, et al.

Blinatumomab and ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse

.

Blood

.

2024

;

144

(suppl

1

):

837

.

10.

Foà

R

,

Bassan

R

,

Vitale

A

, et al.

Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults

.

N Engl J Med

.

2020

;

383

(

17

):

1613

-

1623

.

11.

Jabbour

E

,

Short

NJ

,

Senapati

J

, et al.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

6

):

e433

-

e444

.

12.

Wieduwilt

MJ

,

Yin

J

,

Kour

O

, et al.

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703

.

J Clin Oncol

.

2023

;

41

(suppl

16

):

7006

.

13.

Maude

SL

,

Laetsch

TW

,

Buechner

J

, et al.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

.

N Engl J Med

.

2018

;

378

(

5

):

439

-

448

.

14.

Gardner

RA

,

Finney

O

,

Annesley

C

, et al.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

.

Blood

.

2017

;

129

(

25

):

3322

-

3331

.

15.

Shah

NN

,

Lee

DW

,

Yates

B

, et al.

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

.

J Clin Oncol

.

2021

;

39

(

15

):

1650

-

1659

.

16.

Maude

SL

,

Frey

N

,

Shaw

PA

, et al.

Chimeric antigen receptor T cells for sustained remissions in leukemia

.

N Engl J Med

.

2014

;

371

(

16

):

1507

-

1517

.

17.

Maude

SL

,

Teachey

DT

,

Rheingold

SR

, et al.

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL

.

J Clin Oncol

.

2016

;

34

(suppl

15

):

3011

.

18.

Curran

KJ

,

Margossian

SP

,

Kernan

NA

, et al.

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

.

Blood

.

2019

;

134

(

26

):

2361

-

2368

.

19.

Ghorashian

S

,

Kramer

AM

,

Onuoha

S

, et al.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

.

Nat Med

.

2019

;

25

(

9

):

1408

-

1414

.

20.

Talleur

AC

,

Qudeimat

A

,

Métais

JY

, et al.

Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

.

Blood Adv

.

2022

;

6

(

21

):

5737

-

5749

.

21.

Laetsch

TW

,

Maude

SL

,

Rives

S

, et al.

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

.

J Clin Oncol

.

2023

;

41

(

9

):

1664

-

1669

.

22.

Rives

S

,

Maude

SL

,

Hiramatsu

H

, et al.

S112: tisagenlecleucel in pediatric and young adult patients (PTS) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study

.

HemaSphere

.

2022

;

6

:

13

-

14

.

23.

Pasquini

MC

,

Hu

ZH

,

Curran

K

, et al.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

.

Blood Adv

.

2020

;

4

(

21

):

5414

-

5424

.

24.

Jain

MD

,

Smith

M

,

Shah

NN

.

How I treat refractory CRS and ICANS after CAR T-cell therapy

.

Blood

.

2023

;

141

(

20

):

2430

-

2442

.

25.

Li

AM

,

Rabin

KR

,

Kairalla

J

, et al.

Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: an interim report from Children's Oncology Group (COG) study AALL1731

.

Blood

.

2021

;

138

:

2304

.

26.

Hodder

A

,

Kirkwood

A

,

van der Sluis

I

, et al.

Blinatumomab for first line treatment in intermediate and high risk Down syndrome B-cell acute lymphoblastic leukaemia: initial findings from the ALLTOGETHER1 DS trial

. Paper presented at: EHA Library; 13 June

2024

;

Madrid, Spain

. Session 422215.

27.

Laetsch

TW

,

Maude

SL

,

Balduzzi

A

, et al.

Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

.

Leukemia

.

2022

;

36

(

6

):

1508

-

1515

.

28.

Schultz

LM

,

Baggott

C

,

Prabhu

S

, et al.

Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report

.

J Clin Oncol

.

2022

;

40

(

9

):

945

-

955

.

29.

John

S

,

Curran

KJ

,

Hall

EM

, et al.

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry

.

Blood Adv

.

2025

.

30.

Queudeville

M

,

Stein

AS

,

Locatelli

F

, et al.

Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

.

Cancer

.

2023

;

129

(

9

):

1384

-

1393

.

31.

Ravich

JW

,

Huang

S

,

Zhou

Y

, et al.

Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel

.

Transplant Cell Ther

.

2022

;

28

(

2

):

73.e1

-

73.e9

.

32.

Dourthe

ME

,

Rabian

F

,

Yakouben

K

, et al.

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

.

Leukemia

.

2021

;

35

(

12

):

3383

-

3393

.

33.

Locatelli

F

,

Zugmaier

G

,

Mergen

N

, et al.

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

.

Blood Cancer J

.

2020

;

10

(

7

):

77

.

34.

Myers

RM

,

Taraseviciute

A

,

Steinberg

SM

, et al.

Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL

.

J Clin Oncol

.

2022

;

40

(

9

):

932

-

944

.

35.

Pillai

V

,

Muralidharan

K

,

Meng

W

, et al.

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

.

Blood Adv

.

2019

;

3

(

22

):

3539

-

3549

.

36.

Singh

N

,

Lee

YG

,

Shestova

O

, et al.

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction

.

Cancer Discov

.

2020

;

10

(

4

):

552

-

567

.

37.

Orti

G

,

Sanz

J

,

Garcia-Cadenas

I

, et al.

Analysis of relapse after transplantation in acute leukemia: a comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions

.

Exp Hematol

.

2018

;

62

:

24

-

32

.

38.

Penack

O

,

Abouqateb

M

,

Peczynski

C

, et al.

How risky is a second allogeneic stem cell transplantation?

Leukemia

.

2024

;

38

(

8

):

1799

-

1807

.

39.

Pulsipher

MA

,

Carlson

C

,

Langholz

B

, et al.

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

.

Blood

.

2015

;

125

(

22

):

3501

-

3508

.

40.

Kurosawa

S

,

Fukuda

T

,

Ichinohe

T

, et al.

Center effect on outcomes of second allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia: a nationwide retrospective study

.

Cytotherapy

.

2025

;

27

(

6

):

733

-

743

.

41.

Chen

YH

,

Zhang

X

,

Cheng

YF

, et al.

Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

.

Cytotherapy

.

2020

;

22

(

12

):

755

-

761

.

42.

Orti

G

,

Peczynski

C

,

Boreland

W

, et al.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a Transplant Complications and Paediatric Diseases Working Parties joint EBMT study

.

Leukemia

.

2025

;

39

(

2

):

431

-

437

.

43.

Bader

P

,

Rossig

C

,

Hutter

M

, et al.

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

.

Blood Adv

.

2023

;

7

(

11

):

2436

-

2448

.

44.

Fong

D

,

Tiwari

R

,

Acker

C

,

Clough

L

,

Willert

J.

Leukapheresis and tisagenlecleucel manufacturing outcomes in patients age <3 years with relapsed/refractory acute lymphoblastic leukemia

.

Transplant Cell Ther

.

2023

;

29

(

9

):

579e1

-

579e10

.

45.

Ghorashian

S

,

Jacoby

E

,

De Moerloose

B

, et al.

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study

.

Lancet Haematol

.

2022

;

9

(

10

):

e766

-

e775

.

46.

Annesley

C

,

Lamble

A

,

Summers

C

, et al.

Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL

.

Blood Adv

.

2025

;

9

(

9

):

2068

-

2078

.

47.

Leahy

AB

,

Newman

H

,

Li

Y

, et al.

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

.

Lancet Haematol

.

2021

;

8

(

10

):

e711

-

e722

.

48.

Fabrizio

VA

,

Phillips

CL

,

Lane

A

, et al.

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a pediatric real world CAR consortium report

.

Blood Adv

.

2022

;

6

(

2

):

600

-

610

.

49.

Holland

EM

,

Yates

B

,

Ling

A

, et al.

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

7

):

2167

-

2182

.

50.

Fergusson

NJ

,

Adeel

K

,

Kekre

N

,

Atkins

H

,

Hay

KA

.

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells

.

Front Immunol

.

2023

;

14

:

1178403

.

51.

Fry

TJ

,

Shah

NN

,

Orentas

RJ

, et al.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

.

Nat Med

.

2018

;

24

(

1

):

20

-

28

.

52.

Shalabi

H

,

Qin

H

,

Su

A

, et al.

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

.

Blood

.

2022

;

140

(

5

):

451

-

463

.

53.

Myers

RM

,

DiNofia

AM

,

Li

Y

, et al.

CD22-targeted chimeric antigen receptor- modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy

.

J Immunother Cancer

.

2025

;

13

(

4

):

e011549

.

54.

Gardner

R

,

Annesley

C

,

Finney

O

, et al.

Early clinical experience of CD19 × CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia

.

Blood

.

2018

;

132

:

278

.

55.

Cordoba

S

,

Onuoha

S

,

Thomas

S

, et al.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

.

Nat Med

.

2021

;

27

(

10

):

1797

-

1805

.

56.

Wan

X

,

Li

W

,

Cai

J

, et al.

Safety and efficacy of bicistronic CD19/CD22 CAR T cell therapy in childhood B cell acute lymphoblastic leukemia

.

Blood

.

2024

;

144

(suppl

1

):

681

.

57.

Shah

NN

,

Stevenson

MS

,

Yuan

CM

, et al.

Characterization of CD22 expression in acute lymphoblastic leukemia

.

Pediatr Blood & Cancer

.

2015

;

62

(

6

):

964

-

969

.

58.

Borowitz

MJ

,

Wood

BL

,

Devidas

M

, et al.

Prognostic significance of minimal residual disease in high risk B-ALL: a report from children's oncology group study AALL0232

.

Blood

.

2015

;

126

(

8

):

964

-

971

.

59.

Conter

V

,

Bartram

CR

,

Valsecchi

MG

, et al.

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

.

Blood

.

2010

;

115

(

16

):

3206

-

3214

.

60.

Pieters

R

,

de Groot-Kruseman

H

,

Van der Velden

V

, et al.

Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group

.

J Clin Oncol

.

2016

;

34

(

22

):

2591

-

2601

.

61.

Cabannes-Hamy

A

,

Brissot

E

,

Leguay

T

, et al.

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

.

Haematologica

.

2022

;

107

(

9

):

2072

-

2080

.

62.

Topp

MS

,

Gokbuget

N

,

Stein

AS

, et al.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

.

Lancet Oncol

.

2015

;

16

(

1

):

57

-

66

.

63.

Shang

Q

,

Wang

Y

,

Lu

A

, et al.

Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy

.

Leuk Lymphoma

.

2025

;

66

(

1

):

54

-

63

.

64.

Annesley

C

,

Seidel

KD

,

Wu

Q

, et al.

Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

.

Blood

.

2025

;

146

(

7

):

789

-

801

.

65.

Summers

C

,

Wu

QV

,

Annesley

C

, et al.

Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage

.

Transplant Cell Ther

.

2022

;

28

(

1

):

21

-

29

.

66.

Lamble

AJ

,

Myers

RM

,

Taraseviciute

A

, et al.

KMT2A rearrangements are associated with lineage switch following CD19 targeting CAR T-cell therapy

.

Blood

.

2021

;

138

(suppl

1

):

256

.

67.

Lee

DW

,

Kochenderfer

JN

,

Stetler-Stevenson

M

, et al.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

.

Lancet

.

2015

;

385

(

9967

):

517

-

528

.

68.

Lee

DW

,

Stetler-Stevenson

M

,

Yuan

CM

, et al.

Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation

.

Blood

.

2016

;

128

(

22

):

218

.